Avid Bioservices Inc (CDMO)

[dia76ca]

Another part of the CC I found interesting is here.

Q&A: [17:45 mark]
1. Joe Pantginis – Roth Capital Partners: [ http://www.roth.com & https://roth2.bluematrix.com/docs/pdf/BLUE.pdf ]

JP: First, with the recent financings and the preferred, obviously, you said you have a much stronger balance sheet right now. Would you be able to comment on how this bolstered balance sheet has potentially improved your partnering discussions or helped your partnering discussions because you have this addl. financial leverage?

SK: One of the goals of the financing, obviously, is to ensure that we have the ability to execute on the Phase III study and to bring that all the way across the goal line. Of course, that puts you in a much stronger position with regard to partnering discussions, particularly as they think that you need the capital to complete the study, and they have the upper hand and that's going to work against you in any negotiation. So yes, I think it significantly strengthens our ability, not just executing on Phase III, but all the other areas for business and to continue to explore even broadening potential indications. I think one of the other areas that is exciting that's really heated up is the discussions around just collaborations to combine our agents with some of the other novel immunotherapies, which again, is just further expanding the potential applications of the platform and only adds value to the overall program.